Ophthalmic gene therapy company Beacon Therapeutics was launched in June 2023 with a £96m ($120m) series A financing. The company was created by VC firm Syncona Investment Management, which combined Applied Genetic Technologies Corporation’s late-stage program in X-linked retinitis pigmentosa (XLRP) with two preclinical programs.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?